

Impact of Access Site on Periprocedural Bleeding, Cerebrovascular, and Coronary Events in High-Bleeding-Risk Percutaneous Coronary Intervention: Findings from the RIVA-PCI Trial

Martin Borlich¹ · Uwe Zeymer^{2,3} · Harm Wienbergen⁴ · Hans-Peter Hobbach⁵ · Alessandro Cuneo⁶ · Raffi Bekerredjian⁷ · Oliver Ritter⁸ · Birgit Hailer⁹ · Klaus Hertting¹⁰ · Marcus Hennersdorf¹¹ · Werner Scholtz¹² · Peter Lanzer¹³ · Harald Mudra¹⁴ · Markus Schwefer¹⁵ · Peter-Lothar Schwimbeck¹⁶ · Christoph Liebetrau¹⁷ · Holger Thiele¹⁸ · Christoph Claas³ · Thomas Riemer³ · Ralf Zahn² · Leon Iden¹ · Gert Richardt¹ · Ralph Toelg^{1,19}

¹ Segeberger Kliniken GmbH, Bad Segeberg, Germany; ² Medizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Germany; ³ Institut für Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany; ⁴ Klinikum Links der Weser Bremen, Bremen, Germany; ⁵ Kreisklinikum Siegen, Siegen, Germany; ⁶ Krankenhaus und MVZ Maria-Hilf Stadtlohn, Stadtlohn, Germany; ⁷ Robert-Bosch-Klinikum, Stuttgart, Germany; ⁸ Klinikum Brandenburg Havel, Brandenburg, Germany; ⁹ Katholische Kliniken Essen-Nord-West gGmbH, Essen, Germany; ¹⁰ Krankenhaus Buchholz und Winsen GmbH, Buchholz, Germany; ¹¹ SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany; ¹² Herz- und Diabeteszentrum, Bad Oeynhausen, Germany; ¹³ Gesundheitszentrum Bitterfeld Wolfen, Bitterfeld, Germany; ¹⁴ Städtisches Krankenhaus Neuperlach-München, München, Germany; ¹⁵ Elblandklinikum Riesa, Riesa, Germany; ¹⁶ Klinikum Leverkusen, Leverkusen, Germany; ¹⁷ Kerckhoff-Klinik GmbH, Bad Nauheim, Germany; ¹⁸ Herzzentrum Leipzig der Universität Leipzig, Leipzig, Germany, ¹⁹ Medizinische Fakultät der Christian-Albrechts-Universität zu Kiel, Kiel, Germany

Key words: RIVA PCI, radial access, in-hospital bleeding, access site, percutaneous coronary intervention, dual therapy, high-bleeding-risk

All authors declare: The article is original, with no portion under simultaneous consideration for publication elsewhere or previously published. All authors have read and approved the submission.

Address for correspondence: Martin Borlich, MD
Heart Center, Segeberger Kliniken GmbH, Bad Segeberg, Germany
Am Kurpark 1, Bad Segeberg, Schleswig-Holstein, 23795, Germany
TEL: +49-4551-802-4802; FAX: +49-4552-802-4805
E-mail: martin.borlich@segebergerkliniken.de

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about the work.

Table S1. Data on periprocedural antithrombotics

	TFA	TRA	p-value
Unfractionated Heparin	84.3 % (720/854)	83.4 % (652/782)	0.61
Low molecular weight Heparin	8.1 % (69/854)	11.6 % (91/782)	< 0.05
Bivalirudin	0.0 % (0/854)	0.1 % (1/782)	0.30
ASA	100 % (854/854)	100 % (782/782)	---
GP IIb/IIIa inhibitor	2.9 % (25/854)	1.8 % (14/782)	0.13
Cangrelor	0.6 % (5/854)	0.3 % (2/782)	0.31
Oral P2Y12 inhibitors	72.5 % (619/854)	64.3 % (503/782)	< 0.001
Clopidogrel	63.9 % (546/854)	57.9 % (453/782)	< 0.05
Prasugrel	3.4 % (29/854)	1.4 % (11/782)	< 0.01
Ticagrelor	5.5 % (47/854)	5.2 % (41/782)	0.82

Table S2. Data on coronary intervention

	TFA	TRA	p-value
Data on CAD diagnosis	100 % (854/854)	100 % (782/782)	
1-vessel CAD	24.5 % (209/854)	30.6 % (239/782)	< 0.01
2-vessel CAD	27.8 % (237/854)	32.5 % (254/782)	< 0.05
3-vessel CAD	47.8 % (408/854)	37.0 % (289/782)	< 0.0001
Data on vessels treated	100 % (854/854)	100 % (782/782)	
LAD	46.3 % (395/854)	44.5 % (348/782)	0.48
RCA	34.1 % (291/854)	31.8 % (249/782)	0.34
RCX	25.8 % (220/854)	27.7 % (217/782)	0.36
LM	9.1 % (78/854)	5.9 % (46/782)	< 0.05
CABG	3.7 % (32/854)	0.8 % (6/782)	< 0.0001
Stents implanted per patient			
One stent implanted	61.1 % (522/854)	74.8 % (585/782)	< 0.0001
Two stents implanted	19.8 % (169/854)	15.9 % (124/782)	< 0.05
Three or more stents implanted	19.1 % (163/854)	9.3 % (73/782)	< 0.0001
Stent types per patient			
DES	98.4 % (840/854)	99.1 % (775/782)	0.18
BMS	0.6 % (5/854)	0.0 % (0/782)	< 0.05
Other	1.4 % (12/854)	0.9 % (7/782)	0.34